Refractory Angina (RA) – Market Access and Reimbursement Insights Report – 2025

Refractory Angina (RA) Market Access and Reimbursement Insights

Thelansis’s “Refractory Angina (RA) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Refractory Angina (RA) Overview

Refractory angina (RA) is a debilitating chronic cardiovascular condition defined by persistent ischemic chest pain that remains inadequately controlled despite maximally tolerated medical therapy and the exhaustion of traditional revascularization options like PCI and CABG. Often driven by diffuse atherosclerosis or microvascular dysfunction, RA severely limits patient quality of life and drives recurrent hospitalizations. Diagnosis requires angiographic proof that further anatomical revascularization is unfeasible, alongside functional imaging to confirm reversible ischemia. Management is highly individualized, combining optimized specialized antianginal pharmacotherapy with non-pharmacological interventions like enhanced external counterpulsation (EECP) and advanced structural therapies, such as the percutaneous coronary sinus reducer, to redistribute myocardial blood flow and alleviate symptoms.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Refractory Angina (RA) – Market Access and Reimbursement Insights Report – 2025